FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown
On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in